Study to Assess the Activity of Nexrutine® in Prostate Cancer Patients

Summary

The purpose of the study is to (1) to determine the rate of PSA decline (the number declining). Tissue will be obtained for ancillary studies and (2) to determine the number of patients with a PSA decline to \<1.0 ng/ml at 3 months in patients receiving Nexrutine® with standard radiation therapy. The Secondary Objective is to confirm the tolerability of this regimen. The Third Objective (Ancillary studies) is To evaluate the molecular response of Nexrutine®. Molecular response is defined as changes in the molecular pathways.

Timeline

Start

2011-07

Primary completion

2014-03

Completion

2014-03

Outcome

Outcome not reported

Stopped (Business): “loss of funding”

Drugs

Indications